miR‑486 acts as an oncogene and potential prognostic biomarker in renal cell carcinoma

Sun,Chengwen; Sun,Caihong; Zhou,Yibin; Yang,Ganglong; Li,Guang; Xiang,Congming; Ding,Xiqi; Sun,Jian

doi:10.3892/mmr.2019.10769

miR‑486 acts as an oncogene and potential prognostic biomarker in renal cell carcinoma

Authors:
- Chengwen Sun
- Caihong Sun
- Yibin Zhou
- Ganglong Yang
- Guang Li
- Congming Xiang
- Xiqi Ding
- Jian Sun
View Affiliations

Affiliations: Department of Urology, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu 214062, P.R. China, Department of Critical Care Medicine, People's Hospital of Rizhao, Rizhao, Shandong 276800, P.R. China , Department of Urology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, P.R. China , The Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, Wuxi, Jiangsu 214000, P.R. China
Published online on: October 25, 2019 https://doi.org/10.3892/mmr.2019.10769
Pages: 5208-5215

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRNAs) are well established key players in tumorigenesis. Their emergence as potential diagnostic and prognostic biomarkers for cancer has demonstrated the importance of miRNAs in cancer biology. Although miR‑486 is implicated in many types of cancer, its role in renal cell carcinoma (RCC) remains undetermined. In the present study, real‑time quantitative PCR (qPCR), wound scratch assay, cell proliferation assay, Transwell migration assay and flow cytometry were utilized to detect the miR‑486 transcript and its role in proliferation, migration and apoptosis in RCC. The relationship between miR‑486 expression and clinicopathological variables or overall survival was analyzed using 96 formalin‑fixed paraffin‑embedded (FFPE) RCC samples. The results of the present study revealed significant upregulation of miR‑486 in RCC tissues and cell lines. Moreover, ectopic expression of miR‑486 promoted cell proliferation, mobility and inhibited apoptosis in 786‑O and ACHN cell lines. In addition, the Cox proportional hazard regression analysis revealed that patients with low expression of miR‑486 exhibited a markedly longer overall survival in the univariate and multivariate analyses. In conclusion, our findings indicate that miR‑486 may serve as a novel prognostic biomarker but may also be applied as a new therapeutic approach for the treatment of RCC.

View Figures

View References

1	Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, et al: EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 67:913–924. 2015. View Article : Google Scholar : PubMed/NCBI
2	Patard JJ, Leray E, Rodriguez A, Rioux-Leclercq N, Guillé F and Lobel B: Correlation between symptom graduation, tumor characteristics and survival in renal cell carcinoma. Eur Urol. 44:226–232. 2003. View Article : Google Scholar : PubMed/NCBI
3	Wang M, Gao H, Qu H, Li J, Liu K and Han Z: MiR-137 suppresses tumor growth and metastasis in clear cell renal cell carcinoma. Pharmacol Rep. 70:963–971. 2018. View Article : Google Scholar : PubMed/NCBI
4	Keegan KA, Schupp CW, Chamie K, Hellenthal NJ, Evans CP and Koppie TM: Histopathology of surgically treated renal cell carcinoma: Survival differences by subtype and stage. J Urol. 188:391–397. 2012. View Article : Google Scholar : PubMed/NCBI
5	Powles T, Staehler M, Ljungberg B, Bensalah K, Canfield SE, Dabestani S, Giles R, Hofmann F, Hora M, Kuczyk MA, et al: Updated EAU guidelines for clear cell renal cancer patients who fail VEGF targeted therapy. Eur Urol. 69:4–6. 2016. View Article : Google Scholar : PubMed/NCBI
6	Berezikov E, Guryev V, van de Belt J, Wienholds E, Plasterk RH and Cuppen E: Phylogenetic shadowing and computational identification of human microRNA genes. Cell. 120:21–24. 2005. View Article : Google Scholar : PubMed/NCBI
7	Zamore PD and Haley B: Ribo-gnome: The big world of small RNAs. Science. 309:1519–1524. 2005. View Article : Google Scholar : PubMed/NCBI
8	Ying SY, Chang DC and Lin SL: The microRNA (miRNA): Overview of the RNA genes that modulate gene function. Mol Biotechnol. 38:257–268. 2008. View Article : Google Scholar : PubMed/NCBI
9	Pfeffer SR, Yang CH and Pfeffer LM: The Role of miR-21 in cancer. Drug Dev Res. 76:270–277. 2015. View Article : Google Scholar : PubMed/NCBI
10	Quan J, Jin L, Pan X, He T and Lai Y, Chen P, Lin C, Yang S, Zeng H and Lai Y: Oncogenic miR-23a-5p is associated with cellular function in RCC. Mol Med Rep. 16:2309–2317. 2017. View Article : Google Scholar : PubMed/NCBI
11	Pan X, Quan J, Li Z, Zhao L, Zhou L, Jinling X, Weijie X, Guan X, Li H, Yang S, et al: miR-566 functions as an oncogene and a potential biomarker for prognosis in renal cell carcinoma. Biomed Pharmacother. 102:718–727. 2018. View Article : Google Scholar : PubMed/NCBI
12	Quan J, Li Y, Pan X, Lai Y, He T, Lin C, Zhou L, Zhao L, Sun S, Ding Y, et al: Oncogenic miR-425-5p is associated with cellular migration, proliferation and apoptosis in renal cell carcinoma. Oncol Lett. 16:2175–2184. 2018.PubMed/NCBI
13	Fu H, Tie Y, Xu C, Zhang Z, Zhu J, Shi Y, Jiang H, Sun Z and Zheng X: Identification of human fetal liver miRNAs by a novel method. FEBS Lett. 579:3849–3854. 2005. View Article : Google Scholar : PubMed/NCBI
14	Lang B and Zhao S: miR-486 functions as a tumor suppressor in esophageal cancer by targeting CDK4/BCAS2. Oncol Rep. 39:71–80. 2018.PubMed/NCBI
15	Gao ZJ, Yuan WD, Yuan JQ, Yuan K and Wang Y: miR-486-5p functions as an oncogene by targeting PTEN in non-small cell lung cancer. Pathol Res Pract. 214:700–705. 2018. View Article : Google Scholar : PubMed/NCBI
16	Zhang Y, Fu J, Zhang Z and Qin H: miR-486-5p regulates the migration and invasion of colorectal cancer cells through targeting PIK3R1. Oncol Lett. 15:7243–7248. 2018.PubMed/NCBI
17	He M, Wang G, Jiang L, Qiu C, Li B, Wang J and Fu Y: miR-486 suppresses the development of osteosarcoma by regulating PKC-δ pathway. Int J Oncol. 50:1590–1600. 2017. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
20	Behm-Ansmant I, Rehwinkel J and Izaurralde E: MicroRNAs silence gene expression by repressing protein expression and/or by promoting mRNA decay. Cold Spring Harb Symp Quant Biol. 71:523–530. 2006. View Article : Google Scholar : PubMed/NCBI
21	Liu F, Sang M, Meng L, Gu L, Liu S, Li J and Geng C: miR-92b promotes autophagy and suppresses viability and invasion in breast cancer by targeting EZH2. Int J Oncol. 53:1505–1515. 2018.PubMed/NCBI
22	Luo L, Xia L, Zha B, Zuo C, Deng D, Chen M, Hu L, He Y, Dai F, Wu J, et al: miR-335-5p targeting ICAM-1 inhibits invasion and metastasis of thyroid cancer cells. Biomed Pharmacother. 106:983–990. 2018. View Article : Google Scholar : PubMed/NCBI
23	Zhang X, Yang Y and Feng Z: Suppression of microRNA-495 alleviates high-glucose-induced retinal ganglion cell apoptosis by regulating Notch/PTEN/Akt signaling. Biomed Pharmacother. 106:923–929. 2018. View Article : Google Scholar : PubMed/NCBI
24	Cao L, Wan Q, Li F and Tang CE: MiR-363 inhibits cisplatin chemoresistance of epithelial ovarian cancer by regulating snail-induced epithelial-mesenchymal transition. BMB Rep. 51:456–461. 2018. View Article : Google Scholar : PubMed/NCBI
25	Bitarte N, Bandres E, Boni V, Zarate R, Rodriguez J, Gonzalez-Huarriz M, Lopez I, Javier Sola J, Alonso MM, Fortes P and Garcia-Foncillas J: MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells. Stem Cells. 29:1661–1671. 2011. View Article : Google Scholar : PubMed/NCBI
26	Liu Y, Zhang J, Xing C, Wei S, Guo N and Wang Y: miR-486 inhibited osteosarcoma cells invasion and epithelial-mesenchymal transition by targeting PIM1. Cancer Biomark. 23:269–277. 2018. View Article : Google Scholar : PubMed/NCBI
27	Zhang X, Zhang T, Yang K, Zhang M and Wang K: miR-486-5p suppresses prostate cancer metastasis by targeting Snail and regulating epithelial-mesenchymal transition. OncoTargets Ther. 9:6909–6914. 2016. View Article : Google Scholar
28	Shao Y, Shen YQ, Li YL, Liang C, Zhang BJ, Lu SD, He YY, Wang P, Sun QL, Jin YX and Ma ZL: Direct repression of the oncogene CDK4 by the tumor suppressor miR-486-5p in non-small cell lung cancer. Oncotarget. 7:34011–34021. 2016. View Article : Google Scholar : PubMed/NCBI
29	Goto K, Oue N, Shinmei S, Sentani K, Sakamoto N, Naito Y, Hayashi T, Teishima J, Matsubara A and Yasui W: Expression of miR-486 is a potential prognostic factor after nephrectomy in advanced renal cell carcinoma. Mol Clin Oncol. 1:235–240. 2013. View Article : Google Scholar : PubMed/NCBI
30	Jiang X, Du L, Duan W, Wang R, Yan K, Wang L, Li J, Zheng G, Zhang X, Yang Y and Wang C: Serum microRNA expression signatures as novel noninvasive biomarkers for prediction and prognosis of muscle-invasive bladder cancer. Oncotarget. 7:36733–36742. 2016.PubMed/NCBI
31	Ren C, Chen H, Han C, Fu D, Zhou L, Jin C, Wang F, Wang D, Chen Y, Ma L, et al: miR-486-5p expression pattern in esophageal squamous cell carcinoma, gastric cancer and its prognostic value. Oncotarget. 7:15840–15853. 2016. View Article : Google Scholar : PubMed/NCBI
32	Li C, Zheng X, Li W, Bai F, Lyu J and Meng QH: Serum miR-486-5p as a diagnostic marker in cervical cancer: With investigation of potential mechanisms. BMC Cancer. 18:612018. View Article : Google Scholar : PubMed/NCBI
33	Li W, Wang Y, Zhang Q, Tang L, Liu X, Dai Y, Xiao L, Huang S, Chen L, Guo Z, et al: MicroRNA-486 as a biomarker for early diagnosis and recurrence of non-small cell lung cancer. PLoS One. 10:e01342202015. View Article : Google Scholar : PubMed/NCBI